Skip to content
OpenCapital
Get started
NovoCure logo

NovoCure (NVCR) Q1 2026 Earnings

NVCR·Reported April 30, 2026·Before market open

NovoCure reported Q1 2026 revenue of $174.1M (+12.3% YoY), beat analyst consensus of $167.8M by $6.3M. Diluted EPS came in at $-0.62 (-100.0% YoY), missed the $-0.51 consensus by $0.11.

Revenue
$174.1Mbeat by $6.3M
Consensus: $167.8M
Diluted EPS
$-0.62missed by $0.11
Consensus: $-0.51
SEC

SEC Filings

Earnings release8-K · 0001645113-26-000043
Quarterly report10-Q · 0001645113-26-000042

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about NovoCure's Q1 2026 earnings report.

NovoCure (NVCR) reported Q1 2026 earnings on April 30, 2026 before market open.

NovoCure reported revenue of $174.1M and diluted EPS of $-0.62 for Q1 2026.

Revenue beat the consensus estimate of $167.8M by $6.3M. EPS missed the consensus estimate of $-0.51 by $0.11.

Compared to the same quarter a year prior, revenue grew 12.3% from $155.0M a year earlier and diluted EPS declined 100.0% from $-0.31.

You can read the 8-K earnings release (0001645113-26-000043) and the 10-Q periodic report (0001645113-26-000042) directly on SEC EDGAR. The filing index links above go to sec.gov.